The summaries are free for public
use. The Chronic Liver Disease
Foundation will continue to add and
archive summaries of articles deemed
relevant to CLDF by the Board of
Trustees and its Advisors.
Abstract Details
Lean NAFLD: an underrecognized and challenging disorder in medicine
Rev Endocr Metab Disord. 2021 Jan 3. doi: 10.1007/s11154-020-09621-1.Online ahead of print.
Sheila Maier1, Amanda Wieland2, Melanie Cree-Green3, Kristen Nadeau3, Shelby Sullivan4, Miguel A Lanaspa5, Richard J Johnson5, Thomas Jensen67
Author information
1Division of Endocrinology, University of Colorado School of Medicine, Aurora, CO, USA.
2Division of Hepatology, University of Colorado School of Medicine, Aurora, CO, USA.
3Division of Pediatric Endocrinology, University of Colorado School of Medicine, Aurora, CO, USA.
4Division of Gastroenterology, University of Colorado School of Medicine, Aurora, CO, USA.
5Division of Renal Diseases and Hypertension, University of Colorado School of Medicine, Aurora, CO, USA.
6Division of Endocrinology, University of Colorado School of Medicine, Aurora, CO, USA. Thomas.Jensen@ucdenver.edu.
7Division of Endocrinology, University of Colorado, Denver, Denver, CO, USA. Thomas.Jensen@ucdenver.edu.
Abstract
Classically, Non-Alcoholic Fatty Liver Disease (NAFLD) has been thought to be driven by excessive weight gain and obesity. The overall greater awareness of this disorder has led to its recognition in patients with normal body mass index (BMI). Ongoing research has helped to better understand potential causes of Lean NAFLD, the risks for more advanced disease, and potential therapies. Here we review the recent literature on prevalence, risk factors, severity of disease, and potential therapeutic interventions.